Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Psychostimulant and muscarinic cholinergic agonist.
Marketed in association with other drugs in products indicated, without proof of their efficacy, to improve memory and physical and mental fatigue.
Also used in cosmetic treatments.
Oral use.
At the date of the last update, the authors did not find any published data on its excretion in breast milk.
The limited pharmacokinetic data available (low molecular weight, high pKa) make it likely that it may be transferred to breast milk in a possibly significant amount.
Product with very few bibliographic references, marketed in few countries. Considered a drug of low therapeutic utility (SEFAP 2012, INSALUD 2001).
Until more published data is known about this drug in relation to breastfeeding, known safer alternatives are preferable, especially during the neonatal period and in the event of prematurity.
In general, multiple drug combinations are not recommended, nor are drugs of unproven efficacy.